GALECTIN THERAPEUTICS INC
Galectin Therapeutics Inc (GALT) is a clinical-stage biotechnology company focused on therapies that inhibit galectin proteins, particularly galectin-3, which are implicated in fibrosis and certain cancers. Its lead candidate, belapectin (GR-MD-02), has been evaluated for non-alcoholic steatohepatitis (NASH) with cirrhosis and portal hypertension and has been explored in oncology combinations. The company has no approved products and its value is closely tied to clinical trial outcomes, regulatory decisions, partnership activity and access to financing. With a market capitalisation near $340 million, GALT is a small-cap, high-volatility stock: investors should expect sharp moves around trial readouts and news. Key risks include clinical failure, regulatory setbacks and dilution from future funding rounds. The company holds intellectual property around galectin inhibitors and has sought collaborations to advance programmes. This summary is educational only and not personal financial advice; investors should assess suitability for their own circumstances and tolerance for speculative biotech risk.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Galectin Therapeutics stock as it has significant potential for growth.
Financial Health
Galectin Therapeutics is generating a modest cash flow, indicating steady financial performance but potential for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GALT
MASH Stocks: Could Roche's Deal Spark More M&A?
Roche's $3.5 billion acquisition of 89bio for its liver disease drug highlights the growing MASH treatment market. This deal creates a potential tailwind for other biopharmaceutical companies developing therapies for liver and metabolic conditions.
Published: September 21, 2025
Explore BasketMASH Drug Developers Could Attract M&A in 2025
Roche's $3.5 billion deal to acquire 89bio for its late-stage liver disease drug highlights the immense commercial potential seen in the MASH treatment landscape. This move could trigger a wave of investment and further acquisitions, benefiting other biotech firms with promising therapies for metabolic disorders.
Published: September 19, 2025
Explore BasketMASH Biotech Stocks: What's Next After Roche Deal
Roche's acquisition of 89bio for its late-stage liver disease drug highlights a major strategic investment in the MASH treatment space. This move could increase the valuation of other biotech companies developing therapies for metabolic disorders as they become attractive M&A targets.
Published: September 18, 2025
Explore BasketGLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Published: August 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Trial Readouts Matter
Company value often moves on clinical results and regulatory milestones; meaningful readouts can shift sentiment, though outcomes are uncertain.
Targeting Fibrosis
Galectin‑3 inhibition is a novel therapeutic approach to fibrosis and cirrhosis with scientific rationale, but clinical proof of benefit remains necessary.
Funding & Partnerships
As a small‑cap biotech, progress depends on financing and collaborations; watch for potential dilution and partnership announcements.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
